In Phase 2 Trial, Neflamapimod Aids Cognition in Lewy Body Dementia
After missing primary endpoints in Alzheimer’s trials, this p38 MAPKa inhibitor gained some traction in a test in people with DLB.
ALL NEWS
47 RESULTS
Sort By:
- Most Recent
- Most Commented
Clinical Trials on Alzheimer's Disease (CTAD) 2020 (Virtual Meeting)
BANish Aβ? BAN2401 Antibody Makes Its Move in Phase 3 Program BAN2401 Forges AHEAD into Phase 3, Preclinical AD TRC-PAD Funnel Finally Touches Down Learning Troubles Spied by Smartphone Track with Biomarkers In Phase 2 Trial, Neflamapimod Aids Cognition ...
Current Filters
- Date Range : Sep 2020 to Dec 2020 x